PRECISION BIOSCIENCES INC
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
DTIL$10.60+7.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders’ Equity
Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated · Treasury · TotalStockholders' | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Stock | Equity | |
| Balance- December 31, 2022 | 3,725,689 | $1 | $489,696 | $(428,312) | $(952) | $60,433 |
| Stock option exercises | 1,718 | — | 30 | — | — | 30 |
| Issuance of common stock under employee stock purchase plan | 9,303 | — | 266 | — | — | 266 |
| Share-based compensation expense | — | — | 4,092 | — | — | 4,092 |
| Restricted stock units vested | 16,717 | — | — | — | — | — |
| Proceeds from issuance of common stock, net of issuance cost | 18,012 | — | 416 | — | — | 416 |
| Net loss | — | — | — | (25,060) | — | (25,060) |
| Balance- March 31, 2023 | 3,771,439 | $1 | $494,500 | $(453,372) | $(952) | $40,177 |
| Share-based compensation expense | — | — | 3,874 | — | — | 3,874 |
| Proceeds from issuance of common stock, net of issuance cost | 77,509 | — | 1,881 | — | — | 1,881 |
| Restricted stock units vested | 13,499 | — | — | — | — | — |
| Net loss | — | — | — | (11,891) | — | (11,891) |
| Balance- June 30, 2023 | 3,862,447 | $1 | $500,255 | $(465,263) | $(952) | $34,041 |
| Balance- December 31, 2023 | 4,191,053 | $1 | $509,443 | $(489,631) | $(952) | $18,861 |
| Issuance of common stock under employee stock purchase plan | 9,037 | — | 112 | — | — | 112 |
| Share-based compensation expense | — | — | 2,906 | — | — | 2,906 |
| Proceeds from issuance of common stock to collaboration partners and licensees | 97,360 | — | 905 | — | — | 905 |
| Proceeds from issuance of common stock and warrants through underwritten offering, net of issuance cost | 2,500,000 | — | 4,610 | — | — | 4,610 |
| Proceeds from issuance of common stock through ATM facility, net of issuance cost | 98,943 | — | 1,224 | — | — | 1,224 |
| Restricted stock units vested | 46,861 | — | — | — | — | — |
| Net income | — | — | — | 8,588 | — | 8,588 |
| Balance- March 31, 2024 | 6,943,254 | $1 | $519,200 | $(481,043) | $(952) | $37,206 |
| Share-based compensation expense | — | — | 2,928 | — | — | 2,928 |
| Proceeds from issuance of common stock, net of issuance cost | 25,000 | — | 300 | — | — | 300 |
| Proceeds from issuance of common stock through ATM facility, net of issuance cost | 144,735 | — | 1,531 | — | — | 1,531 |
| Restricted stock units vested | 37,396 | — | — | — | — | — |
| Net income | — | — | — | 32,749 | — | 32,749 |
| Balance- June 30, 2024 | 7,150,385 | $1 | $523,959 | $(448,294) | $(952) | $74,714 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.